Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H24N2O4S2.2ClH |
Molecular Weight | 397.382 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC
InChI
InChIKey=HKASNZKRIQURIX-BZDVOYDHSA-N
InChI=1S/C12H24N2O4S2.2ClH/c1-3-17-11(15)9(7-19)13-5-6-14-10(8-20)12(16)18-4-2;;/h9-10,13-14,19-20H,3-8H2,1-2H3;2*1H/t9-,10-;;/m0../s1
DescriptionSources: https://www.drugs.com/pro/neurolite.html
Sources: https://www.drugs.com/pro/neurolite.html
Bicisate hydrochloride is a ligand that is used to form a complex with technetium. Tc99m Bicisate forms a stable, lipophilic complex that crosses intact cell membranes and blood brain barrier by passive diffusion. The amount of tc99m bicisate is stable in the brain until about 6 hours. Tc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/pro/neurolite.html |
Diagnostic | NEUROLITE Approved UseTc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed Launch Date1994 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/neurolite.html
This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71586979
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
1306099
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB119911
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
DBSALT001533
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
DTXSID4046656
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
B005P07V07
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
100000143314
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
14344-58-2
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY | |||
|
B005P07V07
Created by
admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD